Decorsin & Ornatin
RGD peptide antagonists of platelet integrin GP IIb/IIIa
Last updated: March 14, 2026
Mechanism Disclaimer
Decorsin and ornatin are small RGD-containing peptides isolated from North American leech species that function as potent competitive antagonists of the platelet integrin GP IIb/IIIa (αIIb/β3). This integrin is the most abundant receptor on the platelet surface (~80,000 copies per platelet) and serves as the final common pathway for platelet aggregation by binding fibrinogen to cross-link activated platelets.
Molecular Properties
| Property | Decorsin | Ornatin |
|---|---|---|
| Source | Macrobdella decora | Placobdella ornata |
| Molecular weight | 4,390 Da (39 amino acids) | 5,590 Da (49 amino acids) |
| Key motif | RGD (Arg-Gly-Asp) | RGD (Arg-Gly-Asp) |
| Target | GP IIb/IIIa (αIIb/β3) | GP IIb/IIIa (αIIb/β3) |
| Mechanism | Competitive fibrinogen antagonist | Competitive fibrinogen antagonist |
The RGD Recognition Motif
The Arg-Gly-Asp (RGD) tripeptide is the minimal recognition sequence for integrin receptors. First identified by Pierschbacher and Ruoslahti (1984) in fibronectin, RGD mediates cell adhesion across multiple integrin-ligand pairs. In the hemostatic context, the RGD motif in fibrinogen engages GP IIb/IIIa on activated platelets, forming the cross-bridges that drive platelet aggregation. Decorsin and ornatin exploit this recognition system by presenting an RGD motif in a conformationally constrained peptide scaffold that competes with fibrinogen for integrin binding.
Pharmacological Context
Eptifibatide (Integrilin)
FDA-approved 1998. Cyclic heptapeptide derived from the disintegrin barbourin (Sistrurus miliarius barbouri, pygmy rattlesnake). Contains KGD motif (Lys-Gly-Asp) rather than RGD, providing GP IIb/IIIa selectivity. Used in acute coronary syndromes and percutaneous coronary intervention.
Tirofiban (Aggrastat)
FDA-approved 1998. Non-peptide tyrosine derivative designed as an RGD-mimetic. Small molecule GP IIb/IIIa antagonist used in acute coronary syndromes. Demonstrates the pharmacological principle validated by decorsin/ornatin research.
Although decorsin and ornatin themselves did not advance to clinical development, they contributed significantly to the structural understanding of RGD-integrin interactions and informed the design of clinically successful GP IIb/IIIa antagonists.
Triple Antiplatelet Strategy of SGS
Three Independent Antiplatelet Mechanisms
Adhesion
Platelet-collagen interaction
CalinTethering
vWF-mediated platelet capture
SaratinAggregation
GP IIb/IIIa fibrinogen binding
Decorsin / OrnatinSGS simultaneously blocks all three steps of platelet-mediated primary hemostasis — a strategy no single pharmaceutical agent replicates.